These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3032877)

  • 41. Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for Stages IIB and III esophageal carcinoma: results of a pilot study.
    Calais G; Dorval E; Louisot P; Bourlier P; Klein V; Chapet S; Reynaud-Bougnoux A; Huten N; De Calan L; Aget H; Le Floch O
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):769-75. PubMed ID: 9240645
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma.
    Takamura A; Saito H; Kamada T; Hiramatsu K; Takeuchi S; Hasegawa M; Miyamoto N
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1357-65. PubMed ID: 14630274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma.
    Foo ML; Gunderson LL; Bender CE; Buskirk SJ
    Int J Radiat Oncol Biol Phys; 1997 Nov; 39(4):929-35. PubMed ID: 9369143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Results of radiation therapy in carcinoma of the proximal bile duct (Klatskin tumor).
    González González D; Gerard JP; Maners AW; De la Lande-Guyaux B; Van Dijk-Milatz A; Meerwaldt JH; Bosset JF; Van Dijk JD
    Semin Liver Dis; 1990 May; 10(2):131-41. PubMed ID: 2162565
    [No Abstract]   [Full Text] [Related]  

  • 47. Combined modality treatment in unresectable extrahepatic biliary carcinoma.
    Morganti AG; Trodella L; Valentini V; Montemaggi P; Costamagna G; Smaniotto D; Luzi S; Ziccarelli P; Macchia G; Perri V; Mutignani M; Cellini N
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):913-9. PubMed ID: 10705013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
    Gkika E; Hallauer L; Kirste S; Adebahr S; Bartl N; Neeff HP; Fritsch R; Brass V; Nestle U; Grosu AL; Brunner TB
    BMC Cancer; 2017 Nov; 17(1):781. PubMed ID: 29162055
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma.
    Ohkawa A; Mizumoto M; Ishikawa H; Abei M; Fukuda K; Hashimoto T; Sakae T; Tsuboi K; Okumura T; Sakurai H
    J Gastroenterol Hepatol; 2015 May; 30(5):957-63. PubMed ID: 25376272
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
    Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
    Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiotherapy combined with transarterial infusion chemotherapy and concurrent infusion of a vasoconstrictor agent for nonresectable advanced hepatic hilar duct carcinoma.
    Matsumoto S; Kiyosue H; Komatsu E; Wakisaka M; Tomonari K; Hori Y; Matsumoto A; Mori H
    Cancer; 2004 Jun; 100(11):2422-9. PubMed ID: 15160347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.
    Yu B; Carrasquillo J; Milenic D; Chung Y; Perentesis P; Feuerestein I; Eggensperger D; Qi CF; Paik C; Reynolds J; Grem J; Curt G; Siler K; Schlom J; Allegra C
    J Clin Oncol; 1996 Jun; 14(6):1798-809. PubMed ID: 8656248
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres.
    Lau WY; Ho S; Leung TW; Chan M; Ho R; Johnson PJ; Li AK
    Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):583-92. PubMed ID: 9486608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10.
    Grigsby PW; Lu JD; Mutch DG; Kim RY; Eifel PJ
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):817-22. PubMed ID: 9652843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
    Grigsby PW; Heydon K; Mutch DG; Kim RY; Eifel P
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):982-7. PubMed ID: 11704321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
    Juweid ME; Zhang CH; Blumenthal RD; Hajjar G; Sharkey RM; Goldenberg DM
    J Nucl Med; 1999 Oct; 40(10):1609-16. PubMed ID: 10520699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.